MEETING AGENDA

Cancer Immunotherapy: Where to Go Next

The Banbury Center, Cold Spring Harbor Laboratory, New York, USA
March 16-19, 2019

This meeting was funded by Genentech and Cold Spring Harbor Laboratory with additional support from AbbVie

Organizers:
Ira Mellman, Genentech
Miriam Merad, Icahn School of Medicine at Mount Sinai

This Banbury meeting convened experts to critically review the mechanisms that control tumor response, or underlie the lack of response to current immunotherapy agents. Key themes included: main regulatory pathways that limit antitumor immunity; clinical benefit of novel immunotherapy agents alone or in combination; and novel approaches to accurately assess clinical and biomarker responses and the fundamental features of cancer immunity.

SATURDAY, MARCH 16

Afternoon  Participant arrivals
6:00 pm  Reception, dinner at Robertson House

SUNDAY, MARCH 17

7:15 am  Breakfast at Robertson House

8:30 am  Welcoming and Introductory Remarks
Rebecca Leshan, The Banbury Center, Cold Spring Harbor Laboratory
Ira Mellman, Genentech, South San Francisco, USA
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, USA

8:45 am  SESSION 1: Resistance Mechanisms to Current Checkpoint Inhibitors
Rafi Ahmed, Emory University, Atlanta, USA
Nir Hacohen, Massachusetts General Hospital, Boston, USA
SESSION 2: Tumor Antigen Immunity
Drew Pardoll, Johns Hopkins University, Baltimore, USA
Robert Seder, National Institute of Allergy and Infectious Disease, Bethesda, USA
Lélia Delamarre, Genentech, South San Francisco, USA
Ugur Sahin, University Medical Center, Mainz, Germany

12:30 pm Luncheon at Robertson House

SESSION 3: Tumor Microenvironment Modulation of Tumor Immunity
Diether Lambrechts, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, USA
Sandra Demaria, Weill Cornell Medicine, New York, USA
David Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, USA

6:00 pm Reception, dinner at Robertson House
MEETING PARTICIPANTS

Rafi Ahmed, Emory University
Brian Brown, Icahn School of Medicine at Mount Sinai
Lélia Delamarre, Genentech
Sandra Demaria, Weill Cornell Medicine
Benjamin Greenbaum, Icahn School of Medicine at Mount Sinai
Nir Hacohen, Massachusetts General Hospital
James Heath, Institute for Systems Biology
Alice Kamphorst, Icahn School of Medicine at Mount Sinai
Ephraim Kenigsberg, Icahn School of Medicine at Mount Sinai
Diether Lambrechts, VIB-KU Leuven Center for Cancer Biology
Ira Mellman, Genentech
Miriam Merad, Icahn School of Medicine at Mount Sinai
Drew Pardoll, Johns Hopkins University
Dana Pe’er, Sloan Kettering Institute
Michel Sadelain, Memorial Sloan Kettering Cancer Center
Ugur Sahin, University Medical Center, Mainz
Robert Seder, National Institute of Allergy and Infectious Disease
Brian Topp, Merck & Co
Giorgio Trinchieri, National Cancer Institute
David Tuveson, Cold Spring Harbor Laboratory
Ursula Weiss, Nature
Laurence Zitvogel, Gustave Roussy